IRD

Foundation Fighting Blindness Hosting Webinar for Eye Care Professionals: Best Clinical Practices for Patients with Inherited Retinal Diseases

Retrieved on: 
Tuesday, February 13, 2024

COLUMBIA, Md., Feb. 13, 2024 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host a webinar for eye care professionals on the best practices for managing their patients with inherited retinal diseases (IRDs), including retinitis pigmentosa, Usher syndrome, Stargardt disease, and Leber congenital amaurosis. This webinar will be a part of the March Envisioning a Path to Hope initiative, raising awareness among eye care professionals for the valuable resources the Foundation provides IRD patients and caregivers.

Key Points: 
  • This webinar will be a part of the March Envisioning a Path to Hope initiative, raising awareness among eye care professionals for the valuable resources the Foundation provides IRD patients and caregivers.
  • "With nearly 50 clinical trials underway for emerging IRD therapies and no-cost genetic testing available for patients, eye care professionals can do so much to help IRD patients on their challenging journeys," says Michelle Glaze, director of professional outreach, Foundation Fighting Blindness.
  • "We are delighted to host this informative webinar to empower eye doctors to communicate hope and a path forward for their IRD patients and families."
  • She treats patients in the clinical departments of Acquired Brain Injury and Low Vision Rehabilitation, where she also conducts genetic testing for inherited eye conditions.

Sysmex and Hitachi High-Tech Agree to Collaborate on Development of New Genetic Testing Systems

Retrieved on: 
Thursday, February 8, 2024

TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).

Key Points: 
  • TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).
  • To achieve widespread clinical realization, Sysmex and Hitachi High-Tech will develop more efficient genetic testing systems at a lower cost, aiming at expanding optimal genetic testing for individual diseases.
  • In recent years, there has been active development of assay reagents using next generation sequencer (NGS)(2) in the genetic testing field.
  • Having achieved the milestones in the FS agreement, Sysmex and Hitachi High-Tech have agreed, as the next step, to collaborate on the development of genetic testing systems with a view to their widespread adoption in the clinical setting.

FUJIFILM Cellular Dynamics and Opsis Therapeutics Announce License with BlueRock Therapeutics for iPSC-derived Cell Therapy Candidate

Retrieved on: 
Tuesday, January 23, 2024

an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases.

Key Points: 
  • an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases.
  • BlueRock Therapeutics, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, exercised its option to exclusively license OpCT-001, an iPSC-derived photoreceptor cell therapy for human retinal diseases.
  • Following the option exercise by BlueRock Therapeutics, FUJIFILM Cellular Dynamics and Opsis Therapeutics received an undisclosed license fee and are eligible to receive payments upon achievement of certain development and commercial milestones.
  • OpCT-001 is the first iPSC therapy candidate to be licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.

UTulsa's Hurricane Ventures announces investments in BPEndo, Titan Intake

Retrieved on: 
Monday, December 11, 2023

TULSA, Okla., Dec. 11, 2023 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced two new start-up investments, BPEndo and Titan Intake.

Key Points: 
  • TULSA, Okla., Dec. 11, 2023 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced two new start-up investments, BPEndo and Titan Intake.
  • Hurricane Ventures aims to commercialize intellectual property, create new ventures and attain venture capital funding.
  • "We are excited by the continued momentum of Hurricane Ventures," said Chris Wright, director of UTulsa's Center for Innovation & Entrepreneurship.
  • Created in partnership with 46 Venture Capital, Hurricane Ventures is a funding catalyst for student, alumni, faculty and staff startups.

International Road Dynamics Awarded $4.1 Million North Carolina Weigh Station Maintenance Contract

Retrieved on: 
Monday, November 6, 2023

IRD will maintain and service commercial motor vehicle enforcement technology at 18 locations throughout North Carolina.

Key Points: 
  • IRD will maintain and service commercial motor vehicle enforcement technology at 18 locations throughout North Carolina.
  • SASKATOON, SK, Nov. 6, 2023 /PRNewswire/ - International Road Dynamics Inc. ("IRD"), a wholly-owned subsidiary of Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announced today that it has been awarded a three year $4.1 million contract by North Carolina Department of Transportation ("NCDOT") to maintain, service, repair and calibrate the commercial vehicle enforcement technology located at 18 permanent and virtual truck weigh stations throughout the state.
  • This new contract consolidates and expands the maintenance activities for all active systems in North Carolina into a single statewide maintenance agreement.
  • Most importantly, safety for all drivers is enhanced by removing unsafe trucks and oversized vehicles from the state's roadways."

International Road Dynamics Awarded $2.8 Million Contract for Caltrans Ramp E-Screening System

Retrieved on: 
Wednesday, October 25, 2023

SASKATOON, SK, Oct. 25, 2023 /PRNewswire/ - International Road Dynamics Inc. ("IRD"), a wholly-owned subsidiary of Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announced today that it has been awarded a $2.8 million contract by the California Department of Transportation ("Caltrans").

Key Points: 
  • SASKATOON, SK, Oct. 25, 2023 /PRNewswire/ - International Road Dynamics Inc. ("IRD"), a wholly-owned subsidiary of Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announced today that it has been awarded a $2.8 million contract by the California Department of Transportation ("Caltrans").
  • The contract covers the supply of a high-speed Weigh-In-Motion ("WIM") pre-clearance system and a sophisticated Ramp E-screening system at the Cajon weigh station.
  • The E-screening system will target overweight and unsafe vehicles with the aim of enhancing enforcement efficiency and highway safety.
  • "We are honored to partner with Caltrans in their pursuit of highway safety and efficiency," said Rish Malhotra, IRD's CEO.

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Retrieved on: 
Wednesday, September 13, 2023

This clinical study update is an extension of results provided by Ocugen on April 14, 2023, and includes additional subjects from the high dose group.

Key Points: 
  • This clinical study update is an extension of results provided by Ocugen on April 14, 2023, and includes additional subjects from the high dose group.
  • Ocugen further expanded this Phase1/2 trial to enroll LCA patients with CEP290 gene mutation and pediatric patients with NR2E3, RHO and CEP290 mutations.
  • Our team's unwavering dedication to advancing modifier gene therapy research demonstrated positive preliminary clinical results that offer renewed hope to patients and their families.
  • “In my view, the clinical study update supports the gene-agnostic mechanism of action of OCU400 in RHO patients.

IRD Awarded $13.7 Million Hawaii Traffic Data Collection Contract

Retrieved on: 
Wednesday, September 13, 2023

CTM systems collect traffic volume, speed, vehicle classification, and weight data to support HDOT's continuous traffic monitoring program.

Key Points: 
  • CTM systems collect traffic volume, speed, vehicle classification, and weight data to support HDOT's continuous traffic monitoring program.
  • This agreement involves the operation, data collection, data reporting, maintenance, and repair of all existing HDOT CTM sites, along with additional equipment installation.
  • Traffic data from the CTM systems will be used for traffic planning, noise studies, changes in highway travel patterns, and related factors.
  • Rish Malhotra, IRD's CEO, added, "IRD takes immense pride in our 25-year-long association with HDOT, one that has greatly contributed to the enduring success of their traffic data collection program.

Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress

Retrieved on: 
Wednesday, August 9, 2023

GAAP gross margin for the second quarter of 2023 was 27%, compared to 22% from the second quarter of 2022.

Key Points: 
  • GAAP gross margin for the second quarter of 2023 was 27%, compared to 22% from the second quarter of 2022.
  • Second quarter 2023 non-GAAP¹ gross margin was 29%, compared to 22% from the second quarter of 2022.
  • Second quarter 2023 GAAP operating expense was $41.5 million, compared to $33.6 million in the second quarter of 2022.
  • Second quarter 2023 non-GAAP operating expense was $34.6 million, compared to $26.3 million in the second quarter of 2022.

Quarterhill Announces Strong Q2 Fiscal 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023

Q2 2023 and year-to-date operating results from WiLAN, up to the date of sale on June 15, 2023, are reported as net (loss) income from discontinued operations.

Key Points: 
  • Q2 2023 and year-to-date operating results from WiLAN, up to the date of sale on June 15, 2023, are reported as net (loss) income from discontinued operations.
  • "IRD, our enforcement or commercial vehicle operations unit, had another strong quarter with the highest Q2 revenue in its history, while also generating strong Adjusted EBITDA margins.
  • As a percentage of revenue, SG&A in Q2 2023 was 16% compared to 33% in Q2 2022.
  • Quarterhill will host a conference call to discuss its financial results today at 10:00 AM Eastern Time.